Recorlev® is a potent inhibitor of key adrenal steroidogenesis enzymes
Recorlev inhibits 3 key enzymes involved in the synthesis of cortisol and testosterone at lower concentrations than its racemic counterpart1-3
MOA=mechanism of action.
References: 1. Recorlev. Prescribing Information. Xeris Pharmaceuticals, Inc; 2021. 2. Creemers SG, Feelders RA, de Jong FH, et al. Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing’s syndrome treatment. J Clin Endocrinol Metab. 2021;106(4):e1618-e1630. doi:10.1210/clinem/dgaa989. 3. Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary. 2016;19(6):643-653.